To keep up-to-date with discussions you can subscribe to all postings by clicking the subscribe button below. You can manage your network notifications and set the frequency of emails in your communication preference area.
Return to previous page
Can anyone advise on when toxicity studies are conducted in the drug development process? We are running a number of phase I/II studies where the material safety data sheet indicates that full toxicity studies have not been performed as yet and hence no information on teratogenicity, mutagenicity and etc.
Does anyone have any guidance document on Safe handling of IMPs for new and expectant mothers?
Any advice on this issue would be greatly appreciated.
Need help with networks?
If you have any queries about our networks you can get in touch via:
Networks – [email protected]
Local Practice Forums (LPFs) - [email protected]
If you need to report a post then please use the report button within a discussion.